Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

A0200000

Acetylsalicylic acid

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula lineal:
2-(CH3CO2)C6H4CO2H
Número de CAS:
50-78-2
Peso molecular:
180.16
Beilstein:
779271
Número MDL:
MFCD00002430
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329770581
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

aspirin

fabricante / nombre comercial

EDQM

mp

134-136 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

Clave InChI

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Información sobre el gen

human ... PTGS1(5742) , PTGS2(5743)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Acetylsalicylic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1044006

Aspirin, United States Pharmacopeia (USP) Reference Standard

Y0001460

Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard

1609807

Salsalate, United States Pharmacopeia (USP) Reference Standard

1696200

Trisalicylic acid, United States Pharmacopeia (USP) Reference Standard

BP617

Aspirin, British Pharmacopoeia (BP) Reference Standard

PHR1940

Aspirin Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1941

Aspirin Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1942

Aspirin Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogramas

Exclamation mark
GHS07

Palabra de señalización

Warning

Frases de peligro

H302

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

482.0 °F

Punto de inflamabilidad (°C)

250 °C

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 7

1 of 7

Salicylic acid United States Pharmacopeia (USP) Reference Standard

USP

1609002

Salicylic acid

Salicylic acid British Pharmacopoeia (BP) Reference Standard

BP775

Salicylic acid

Aspirin Impurity E Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1941

Aspirin Impurity E

Salicylic acid impurity B European Pharmacopoeia (EP) Reference Standard

Y0000405

Salicylic acid impurity B

Mefenamic acid European Pharmacopoeia (EP) Reference Standard

M0252600

Mefenamic acid

Salicylic acid BioXtra, ≥99.0%

Sigma-Aldrich

S5922

Salicylic acid

Salicylic acid certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Supelco

52341

Salicylic acid

Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico